Has Reginald Low, MD received payments from drug or device companies?

Yes. Drug and device makers reported $37,250 in general payments to Reginald Low, MD across 65 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Reginald Low, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Reginald Low, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Reginald Low, MD

Cardiovascular Disease · Sacramento, CANPI 1821070780

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $26,400 of the $37,250 with a category attached, or 70.9%. Shockwave Medical, Inc accounts for 74.1% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2023 at $21,058 and has fallen 98.2% since, to $384 in 2025. Among cardiovascular disease clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$37,250in general payments, 2019–2025

Across 65 payments — averaging $573.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Shockwave Medical, Inc$28K
Boston Scientific$8K
Recor Medical Inc$285
Biotronik Inc.$266
Heartflow, Inc.$218
Medtronic$199
plus $539 from 9 others

$103,741in research payments, 2019–2025

Across 54 payments — averaging $1921.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Abbott$64K
Boston Scientific$24K
Edwards Lifesciences$16K

What the payments were for

Consulting fees$6,55018%
Speaking & faculty fees$26,40071%
Travel & lodging$1,0053%
Food & beverage$3,2959%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Shockwave Medical, Inc	17	$27,586
Boston Scientific	27	$8,157
Recor Medical Inc	3	$285
Biotronik Inc.	4	$266
Heartflow, Inc.	2	$218
Medtronic	2	$199
Abiomed	1	$128
Abbott	1	$106
Alnylam Pharmaceuticals Inc.	1	$102
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	1	$91
Philips North America LLC	2	$43
Sanofi-aventis U.S. LLC	1	$22
Regeneron Healthcare Solutions, Inc.	1	$18
E.r. Squibb & Sons, L.L.C.	1	$15
Terumo Medical Corporation	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$27,302
GENERAL VASCULAR ACCESS$6,000
GENERAL - THERAPIES$1,146
FFRct$203
Paradise Ultrasound Renal Denervation System$152
COREVALVE EVOLUT R$137
GENERAL - STENTS$136
Impella$128
SYNERGY$119
Pantera LEO$118
ReCross$118
Orsiro Mission$118
PK Papyrus$118
PARADISE RENAL DENERVATION SYSTEM$115
COROFLOW$106

How this compares

$37,250 in reported general payments places this provider in the 90th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California →

Medicare billing

Part B allowed, 2024

$46,601

Medicare patients

1,012

Services billed

1,446

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	92	$116,345
Repatha SureclickEvolocumab	37	$28,740
Praluent PenAlirocumab	34	$20,805
JardianceEmpagliflozin	19	$15,663
Flecainide Acetate	68	$2,777
Metoprolol Succinate	93	$1,990
Atorvastatin Calcium	125	$1,904
Valsartan	52	$1,453
Telmisartan	45	$1,397
Rosuvastatin Calcium	67	$1,094
Eplerenone	12	$1,076
Ezetimibe	34	$821
Rabeprazole Sodium	12	$803
Pravastatin Sodium	12	$756
Amlodipine Besylate	89	$699

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Sacramento

Jason RogersSacramento$4.4M
Gagan SinghSacramento$1.2M
Thomas SmithSacramento$942K
Edris AmanSacramento$516K
Garrett WongSacramento$504K
William BommerSacramento$194K
Jeffrey SouthardSacramento$193K
Andrea SoaresSacramento$159K
Ted LoveHillsborough$102.8M
Paul KurthSanta Barbara$6.1M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →